Long-term use of ranibizumab for the treatment of age-related macular degeneration a review of the clinical and cost-effectiveness and guidelines
The purpose of this review is to evaluate the clinical evidence, cost information, and guidelines to determine if there is evidence to support dosing regimens of 15 or more injections of ranibizumab for the treatment of age-related macular degeneration (AMD)
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
11 March 2014, 2014
|
| Series: | Rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The purpose of this review is to evaluate the clinical evidence, cost information, and guidelines to determine if there is evidence to support dosing regimens of 15 or more injections of ranibizumab for the treatment of age-related macular degeneration (AMD) |
|---|---|
| Item Description: | Title from PDF caption. - "CADTH rapid response service." |
| Physical Description: | 1 PDF file (25 pages) illustration |